◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound WATCH-LIST MEDIUM-HIGH

Thymosin Alpha 1

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict WATCH-LIST MEDIUM-HIGH

"Tα1 has the cleanest safety record of any immune-modulating peptide in this research base (>11,000 patients studied across 30+ trials, <1% serious adverse events, approved in 35+ countries for 30+ years), so the floor on harm is low. Confidence is MEDIUM-HIGH because: (a) for the indications it's approved for — chronic HBV, chronic HCV non-responder adjunct, sepsis-ICU adjunct, chemotherapy immune support, primary immunodeficiency — the evidence is A-tier, multi-decade, multi-country, FDA-orphan-designated; (b) for users in this archetype's actual likely use case — heavy-training-block immune support + acute illness recovery — the evidence is mostly **mechanistic extrapolation from approved indications + Castell-style post-marathon URTI immune-dip literature + peptide-clinic anecdote**, not direct sport-medicine RCT. Verdict is WATCH-LIST not STRONG-CANDIDATE because a user in this archetype is a healthy 20yo with intact immune function — the marginal benefit is small in the absence of an active immune challenge. PRN-during-illness use is the highest-leverage application; reasonable to keep a vial on hand for cold/flu season or post-illness convalescence. Verdict would upgrade to OPTIONAL-ADD if a user in this archetype develops chronic post-training URTI pattern (>3 colds in 3 months), gets an acute moderate-to-severe illness needing recovery support, or has a competition prep block where any immune dip is high-cost. Would upgrade further to STRONG-CANDIDATE if a sport-medicine immune-support RCT in trained athletes reads positive. Verdict would downgrade to SKIP-FOR-NOW only if a major safety signal emerged (none currently in 30 years of clinical use)."

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, high cognitive workload, healthy baseline (this-archetype, general use)
    WATCH-LIST

    Marginal benefit in healthy baseline state; not a daily-stack member; not a cognitive enhancer. The signal-to-noise is too low to justify daily prophylactic use in someone with intact immune function.

  • 20-30, combat athlete with active illness or post-illness convalescence (the user's actual likely use case)
    OPTIONAL-ADD-PRN

    (highest-value the user application). When there's an active immune challenge to respond to — acute illness, lingering post-viral fatigue, post-COVID convalescence, chronic-URTI pattern — Tα1 has a reasonable evidence-base + mechanism-aligned signal + clean safety profile. Recommended: keep 2 vials on hand for PRN deployment.

  • 20-30, combat athlete in heavy fight-camp / training-block
    OPTIONAL-ADD

    (insurance use). Mechanistic case for protecting against training-load-driven immunosuppression (Castell open-window theory + Tα1's anti-cortisol-thymocyte-apoptosis mechanism). Anecdotal community use. Marginal benefit for healthy 20yo; reasonable if a user in this archetype develops chronic-URTI-during-camps pattern.

  • 30-50, executive maintenance, healthy baseline
    WATCH-LIST

    Same logic as 20-30 — minimal active immune challenge, marginal benefit. Reasonable for cold/flu season insurance if illness-prone.

  • 50+, mild cognitive decline
    OPTIONAL-ADD

    Aging immunosenescence (thymic involution, reduced T-cell output) is the mechanistic sweet spot for Tα1. Vaccine response enhancement, reduced infection susceptibility, general immune competence. 1-2 cycles of 12 weeks per year is reasonable. STRONG-CANDIDATE in older-age archetype.

  • Anxiety-prone
    OPTIONAL-ADD

    (no specific concern). Not anxiogenic; no documented mood effects. Subjectively boring at baseline.

  • High athletic load, tested status (WADA-relevant)
    OPTIONAL-ADD

    (verify each year). As of 2026, Tα1 is not on the WADA prohibited list (immune modulator without performance-enhancement class). Verify current year's prohibited list before competition use — peptide immunomodulators have been added to the prohibited list historically. Irrelevant for users in this archetype (untested).

  • Sleep-disordered
    NEUTRAL

    Not a sleep tool. Some users report mild sleep-onset issues in first week; minority report deeper sleep with reduced inflammation. Not significant either direction.

  • Recovery-focused (post-injury, post-illness, post-surgery)
    STRONG-CANDIDATE

    for post-illness or post-surgery contexts. WATCH-LIST for post-injury without infection component (BPC-157/TB-500 are the right tools for clean orthopedic injury without immune challenge).

  • Strength/anabolic-focused
    WATCH-LIST

    Wrong category — not anabolic, not direct performance enhancement. Useful only for the immune-support indirect support of training continuity.

  • Chronic infection (HBV, HCV, recurrent infection, CFS, post-viral syndrome)
    STRONG-CANDIDATE

    This is the on-label home turf — multi-decade A-tier evidence base. Physician-managed protocol preferred (Zadaxin Rx via compounding or international pharmacy).

  • Post-chemotherapy / immune compromise
    STRONG-CANDIDATE

    under physician oversight.

  • Aging immunosenescence (60+, frequent infections)
    STRONG-CANDIDATE

    Mechanism-aligned with thymic involution; multi-trial evidence base for vaccine response + infection reduction in elderly.

▸ Subjective experience (deep)

For a typical user on 1.6 mg SC 2× weekly (the standard dose):

  • In a healthy baseline immune system: Often nothing. Tα1 has minimal felt-effect in users who don't have an active immune challenge — there's nothing to re-balance. Mild injection-site reaction (small welt, transient redness) is the primary palpable effect. Some users report subtle "feels slightly more resilient" or "fewer little colds"; many report indistinguishable-from-nothing.
  • In an active acute illness (cold, flu, post-COVID, lingering viral): Subjectively faster recovery — energy returns 1-3 days earlier than typical illness duration, lingering post-viral fatigue resolves faster, "feels like the illness is letting go." Onset typically within 3-7 days of starting the protocol during an active illness.
  • In a post-illness convalescence context: Faster return to baseline training capacity, less "wiped out" feeling weeks after the acute illness clears. Useful for post-flu / post-mono / post-COVID periods where the acute illness is over but baseline energy hasn't returned.
  • In a heavy-training-block insurance context: The intended outcome is non-illness — you don't get the cold you would have gotten. Hard to verify subjectively. The plausible signal is "I expected to feel run down by week 6 of camp and I don't."

Honesty about variability: "I felt nothing on Tα1, but I also didn't get sick this winter for the first time in years" is a representative report. The effect is what doesn't happen rather than what does. Users running it during illness or post-illness give cleaner positive reports (faster recovery, energy returning earlier than expected). Healthy-baseline users running it as daily insurance often report nothing distinguishable from placebo. The signal-to-noise is decisively highest in users with an active or recent immune challenge.

Injection experience: SC is the standard route. Inject into abdominal SC fat (2+ inches from navel), thigh, or flank. Use insulin syringe (29-31g × 1/2"). Standard dose: 1.6 mg SC. Reconstitute as below (Sourcing section). Mild burn during push, settles in <30 seconds. Bruising / minor bumps occasional, especially abdominal sites. Rotate sites. Some users report transient mild flu-like feeling 2-12 hours post-injection during the first 1-2 doses (this is the immune system "waking up" — interpretable as Tα1-is-working signal, resolves with continued dosing).

▸ Tolerance + cycling deep dive
  • Tolerance buildup: None documented. No receptor downregulation in mechanism (TLR9/TLR2 agonism doesn't drive tolerance the way GPCR signaling does). Patients running 24-48 week continuous chronic-infection protocols don't show waning effect.
  • Recommended cycle for users in this archetype-archetype PRN: Run during acute illness or convalescence; off when recovered. No artificial cycle limits — use as needed. For optional insurance protocols (heavy-training-block, cold/flu season), 8-12 week blocks 1-2× per year are reasonable.
  • Reset protocol: Not applicable. Peptide clears within hours; downstream immune effects fade over 2-4 weeks post-cycle. No taper required.
▸ Stacking deep dive

Synergistic with

  • interferon-α (in approved indications HBV/HCV). Documented synergistic NK cell activation in chronic viral hepatitis. Not relevant for users in this archetype unless he develops chronic HBV/HCV — flagging only.
  • Vaccines. Tα1 enhances vaccine immunogenicity in elderly and immunocompromised. Could be relevant: if the user gets a flu shot or future COVID booster during a heavy-load training period, running 1.6 mg SC twice weekly × 4 weeks straddling the vaccination would mechanistically enhance antibody response — though for a healthy 20yo, the marginal benefit is modest.
  • Chemotherapy agents. Mechanism-additive, established clinical use. Not relevant for users in this archetype.
  • NAC + curcumin + Vit C + Vit D3 + magnesium (already in V4) — antioxidant and immune-cofactor infrastructure that Tα1 operates on top of. Clean adjuncts.
  • Glutathione (oral, IV, or NAC-derived). Mechanism-additive — supports cellular redox during immune challenge. Listed as related-slug in pep-pedia.
  • Zinc 15-30 mg during acute illness. Mechanism-additive (zinc is immune cofactor); strong stand-alone evidence for cold duration.

Avoid stacking with

  • Immunosuppressive agents (cyclosporine, tacrolimus, mycophenolate, post-transplant biologics). Absolute contraindication. Mechanism-opposing; documented harm in transplant patients (fatal immune hemolytic anemia, graft rejection).
  • High-dose corticosteroids (prednisone >20 mg/d, dexamethasone). Pharmacodynamic antagonism — Tα1 blocks steroid-induced thymocyte apoptosis, partially neutralizing immunosuppressive effect of steroids. Not relevant for users in this archetype (no steroid use). If a clinician is intentionally using steroids for immunosuppression, Tα1 should be discontinued.
  • Active anti-thymocyte globulin or anti-T-cell biologics. Mechanism-opposing. Not relevant for users in this archetype.

Neutral / safe co-administration

  • All V4 daily core supplements
  • Modafinil, bromantane, Adamax/Semax, ALCAR, taurine, apigenin (V5 plans)
  • Cerebrolysin cycles
  • BPC-157 + TB-500 (different lanes — repair vs immune; can co-administer without conflict, but typically don't run all three simultaneously due to cost + injection burden + signal-attribution problems)
  • KPV (immune-modulating tripeptide; theoretical complementarity, no head-to-head data)
  • LL-37 (cathelicidin antimicrobial peptide; theoretical complementarity for active infection)
  • Standard MMA-relevant supplements (electrolytes, beta-alanine, creatine)
  • Caffeine (V4 ramp)
  • Alcohol (a user in this archetype is alcohol-free, non-issue)
▸ Drug interactions deep dive
  • CYP enzymes: Tα1 is a peptide cleared by general peptidases — no significant CYP induction or inhibition. Does not affect modafinil (CYP3A4), oral contraceptives, statins, or any other this archetype's typical stack member.
  • Hormonal contraceptives: No interaction. (Irrelevant for users in this archetype.)
  • Anticoagulants / antiplatelets: No documented interaction.
  • Alcohol: No interaction (a user in this archetype is alcohol-free, non-issue).
  • NSAIDs: No interaction. NSAIDs don't oppose Tα1's immune-modulation lane (unlike their interaction with BPC-157/TB-500's tissue-repair lane).
  • Vaccines: Mechanism-additive — Tα1 enhances vaccine immunogenicity. Considered a feature, not a bug.
  • Immunosuppressants: Absolute contraindication (see above).
  • Corticosteroids: Pharmacodynamic antagonism — monitor combination. Not relevant for users in this archetype.
▸ Pharmacogenomics
  • Minimal published pharmacogenomic data specific to Tα1 response. The peptide is cleared by general peptidases; there is no single CYP polymorphism, transporter SNP, or receptor variant documented to alter its profile.
  • Theoretical / indirect:
    • TLR9 polymorphisms. TLR9 is a primary Tα1 target. Several TLR9 variants (rs5743836 −1237T>C, rs187084 −1486T>C) modify TLR9 expression and signaling — could in principle modify Tα1 response magnitude. No direct human data linking specific TLR9 variants to Tα1 efficacy. Could potentially be assessed from 23andMe raw data via Promethease or similar tools.
    • TLR2 polymorphisms. Similar story — TLR2 is the secondary target; variants exist but no direct Tα1 efficacy data.
    • Cytokine-axis variants (IFN-γ, IL-12, IL-2). Could modify magnitude of Th1 response. No actionable data.
    • HLA / immune-axis variants. Heavy-effect on immune phenotype but no documented Tα1-specific interaction.
  • Action item post-23andMe (June 2026): Optional — scan results for TLR9 / TLR2 variants and broader immune-axis SNPs. Not decision-changing for first PRN use; potentially refine prophylactic protocols if the user moves to heavier prophylactic dosing.
▸ Sourcing deep dive
Path Vendor Cost (5 mg vial / 10 mg vial) Reliability Notes
Compounding pharmacy (US, with Rx) Various 503A $80-200 / 5 mg vial high Tα1 is NOT on FDA Category 2 restricted bulks list (unlike BPC-157, TB-500, GHK-Cu). Some compounding pharmacies prepare Tα1 with physician Rx. Access varies. Worth asking a peptide-aware physician — this is the cleanest supply chain path.
International Rx (Zadaxin) Brand Zadaxin via international pharmacy $200-500 / month high Approved as Zadaxin in 35+ countries. International pharmacies (Indian, Mexican, Italian) can ship to US; expensive but pharmaceutical-grade. Good for chronic-infection use; overkill for PRN immune support.
Gray-market US research peptide Limitless Life Nootropics $40-90 / 5 mg vial high US-manufactured, COA published, same-day shipping. Strong reputation. Listed in related-peptide protocols (BPC-157, TB-500, etc.).
Gray-market US research peptide Core Peptides (corepeptides.com) $50-100 / 5 mg vial; multi-vial discounts high US-based, COA published, >99% HPLC + MS. Top community pick for cost-quality.
Gray-market US research peptide Pharma Lab Global ~$40-80 / 5 mg vial medium-high International gray-market vendor, COA published, decent reputation.
Gray-market US research peptide Modern Aminos ~$40-90 / 5 mg vial medium-high US-based vendor, established, COA published.
Gray-market US research peptide Peptide Sciences ~$60-120 / 5 mg vial medium-high Long-running US vendor, COA published. Acceptable backup.

Cost math for users in this archetype (PRN active-illness use case):

  • 1.6 mg SC twice weekly × 3-4 weeks = ~10-13 mg
  • ~2-3 × 5 mg vials per illness episode
  • At Limitless Life: 2-3 × $60 = $120-180 per illness episode
  • Recommended: keep 2 vials (~$120) on hand; deploy when next moderate illness hits

Cost math for users in this archetype (heavy-training-block insurance):

  • 1.6 mg SC weekly × 12 weeks = ~20 mg
  • ~4 × 5 mg vials per camp
  • At Limitless Life: 4 × $60 = $240 per camp

Cost math for users in this archetype (cold/flu season insurance):

  • 1.6 mg SC weekly × 12 weeks = ~20 mg
  • ~4 × 5 mg vials per season
  • At Limitless Life: 4 × $60 = $240 per season

Recommended starting position: Keep 2 vials on hand (~$120-160) for PRN illness use. Skip prophylactic protocols unless a user in this archetype develops chronic illness pattern.

Sourcing strategy:

  • Order 2-3 weeks before predicted need (cold/flu season; pre-camp; or just keep on standing-stock)
  • Cold chain: lyophilized powder shelf-stable at room temp short-term; store unopened lyophilized vials in fridge (2-8°C); store reconstituted vials in fridge and use within 30 days. Do not freeze reconstituted solution.
  • Verify COA on each batch — HPLC purity ≥98%, mass spec confirming ~3,108 Da, endotoxin <0.5 EU/mg

Quality verification on receipt:

  • Sealed crimp-top vial, intact rubber stopper, lyophilized powder white/off-white
  • Vial label matches order; lot number traceable to COA
  • COA from independent third-party lab (not just internal "QC certificate")
  • If powder discolored, liquid in vial, or seal compromised → discard, contact vendor
▸ Biomarkers to track (deep)

Baseline (before first PRN use, optional given low-stakes nature)

  • CBC with differential — lymphocyte count, neutrophil count, total WBC. Already part of the user's 2026 bloodwork plan.
  • CD4/CD8 ratio (specialty test) — optional baseline for monitoring thymic competence over years.
  • NK cell count + activity (specialty test) — optional for athletes in heavy-load contexts.
  • hsCRP, IL-6 — already part of the user's 2026 bloodwork plan; baseline systemic inflammation.
  • Illness frequency log — track URTIs / colds / flu over a baseline 6-12 month period before initiating any prophylactic protocol. This is the cheapest and most useful measurement — without a baseline frequency, you can't tell if Tα1 is reducing your illness rate.
  • HRV trend (if a user in this archetype has a wearable like Whoop / Oura / Garmin) — chronic HRV depression is a documented marker of immune dip / overtraining. Useful for timing immune-support PRN protocols.

During use

  • Symptom-resolution time (when used PRN for acute illness): days to symptom-50%-resolved, days to full recovery, comparison to typical illness duration. Subjective but useful.
  • Energy / training capacity recovery (post-illness convalescence): days to return to ~80% baseline capacity.
  • Injection-site reactions: track for escalation patterns.
  • Any unusual symptoms: rare but track.

Post-use

  • Updated illness frequency log: did the protocol reduce frequency / severity / duration of illnesses vs baseline? This is the only way to evaluate prophylactic protocols rigorously.

Annually (if running prophylactic cycles)

  • Repeat CBC, hsCRP, IL-6 (already part of annual bloodwork)
  • CD4/CD8 ratio if running multiple cycles per year (specialty test)
  • Decision: continue 1-2 cycles/yr maintenance vs PRN-only
▸ Controversies / open debates Live debate
  • TESTS Phase 3 sepsis trial negative for primary endpoint (2025). The largest definitive Tα1 RCT in history (1,106 patients) failed its primary mortality endpoint, despite the smaller ETASS trial (Wu 2013) suggesting benefit. Subgroup analysis hinted at benefit in elderly and diabetic populations. Honest read: sepsis adjunct use is now genuinely uncertain at the population level; the indication may benefit specific subgroups but not the average septic patient. This moves overall confidence in Tα1's "everywhere it's been claimed to work" from HIGH to MEDIUM-HIGH, even though chronic-infection / chemo-support indications remain solid.
  • DAA era and HCV indication relevance. Tα1's HCV non-responder indication was meaningful in the pre-DAA era. Modern direct-acting antivirals (sofosbuvir + velpatasvir, glecaprevir/pibrentasvir) achieve >95% sustained virological response in 8-12 weeks for most genotypes — Tα1 is functionally obsolete for HCV. The HCV approval is now historical, not clinically relevant in 2026.
  • Healthy-user prophylactic protocols are evidence-thin. All A-tier Tα1 evidence is in patients with documented immune challenge — chronic infection, sepsis, cancer, primary immunodeficiency, vaccine-low-responders. Prophylactic use in healthy users (cold/flu season insurance, training-camp insurance) is mechanism-extrapolation + community anecdote, not RCT-validated. Conservative read: don't pay for prophylactic protocols expecting RCT-grade benefit. The PRN-during-illness use case is much better supported.
  • Overlap with broader immune-support tools (zinc, elderberry, vitamin D, sleep). Tα1's PRN immune-support effect competes with cheaper, OTC, evidence-based interventions. Zinc lozenges have stronger cold-duration RCT evidence than any Tα1 prophylactic protocol. Cost-effectiveness comparison: Tα1 ~$120/illness episode vs zinc ~$5/episode. Tα1's incremental benefit over zinc + sleep + Vit D adequate is unclear.
  • Athletic-immune-support evidence is mechanism-only. No published RCT of Tα1 in trained athletes. The Castell open-window literature documents post-heavy-load URTI susceptibility; Tα1's mechanism (anti-cortisol-thymocyte-apoptosis, T-cell maturation) maps onto this; the community uses it for this purpose. But the human RCT for athletes specifically is missing. This is the single biggest gap for users in this archetype's likely use case.
  • TLR9/TLR2 dual agonism — is this all of the mechanism? The 2010s research clarified TLR9/TLR2 as primary targets, but Tα1's effects on dendritic cells, T cells, NK cells, and antioxidant enzymes may involve additional pathways not fully characterized. Mechanism is "more known than for most peptides, less known than for FDA-approved small molecules."
  • Long COVID / PASC indication is preliminary. The Romano 2023 Frontiers in Immunology study showed restoration of immune homeostasis with normalized T-cell populations in PASC patients. Single study, small cohort, single lab — needs replication. The mechanism is plausible (PASC has documented immune-dysregulation features), but evidence is B-tier.
  • My prior verdict humility. WATCH-LIST for users in this archetype-archetype is anchored in (a) clean safety profile makes downside small, (b) PRN-during-illness has reasonable mechanistic + evidence base, (c) healthy-baseline daily prophylactic use is evidence-thin and lower-leverage than free interventions (sleep, hand hygiene, Vit D adequacy, zinc lozenges during illness). Verdict could upgrade to OPTIONAL-ADD if a user in this archetype develops chronic post-training URTI pattern; could upgrade to STRONG-CANDIDATE for older the user (40+) when immunosenescence becomes relevant; could downgrade only if a major safety signal emerged (none currently).
▸ Verdict change log
  • 2026-05-06 — Initial verdict: WATCH-LIST PRN (MEDIUM-HIGH confidence) for users in this archetype-archetype healthy 20yo combat athlete. OPTIONAL-ADD-PRN for active illness recovery, post-illness convalescence, or heavy training-block insurance. STRONG-CANDIDATE in older-age archetype (50+) for immunosenescence support. Concrete protocol: 1.6 mg SC twice weekly × 2-4 weeks during active illness or post-illness convalescence; 1.6 mg SC once weekly × 8-12 weeks for optional fight-camp or cold/flu season insurance. Sourcing via Limitless Life or Core Peptides at ~$60-120 for 2 vials kept on standing stock for PRN deployment. Reassess if illness pattern develops (>3 colds in 3 months, lingering post-viral fatigue, fight-camp-driven URTI). Hard-stop trigger: organ transplant scenario (absolute contraindication — irrelevant for users in this archetype); active autoimmune disease in flare.
▸ Open questions / gaps Open
  1. Athletic immune-support RCT. No published RCT of Tα1 in trained athletes. The community uses it during heavy training blocks; the mechanism is plausible (anti-cortisol-thymocyte-apoptosis, T-cell maturation in stress contexts); but the direct human RCT is missing. Action: re-search 2026-2028 for sport-medicine immune-support trials. A single positive trial would move verdict to OPTIONAL-ADD.
  2. Healthy-user prophylactic protocol evidence. Cold/flu season insurance and training-camp insurance protocols are community-derived; no RCT in healthy users. Action: skip prophylactic protocols for now; focus PRN use during active immune challenges where the evidence is stronger.
  3. Optimal duration for PRN active-illness use. Community standard 2-4 weeks during illness; Romano 2023 used 12 weeks for PASC. Action: start with 2-3 weeks for typical acute illness; extend if symptoms persist beyond expected duration.
  4. Long COVID / PASC indication. Single Romano 2023 study; needs replication. If a second positive trial emerges, this becomes a relevant indication for any the user post-COVID convalescence scenario.
  5. TESTS sepsis Phase 3 negative — implications for other indications? The TESTS failure shouldn't necessarily invalidate chronic-infection or chemo-support indications (different mechanisms, different patient populations), but it does suggest that the largest controlled trials don't always replicate the smaller-trial-derived signal. Watch for definitive Phase 3 trials in other indications.
  6. Cost-effectiveness vs cheaper interventions. Tα1 PRN ~$120/illness episode vs zinc lozenges + sleep + Vit D adequate ~$10/episode. Honest framing: for healthy 20yo with intact immunity, the marginal benefit of Tα1 over OTC alternatives is uncertain. Reserve for moderate-severe illness or lingering post-viral context where OTC interventions have failed.
  7. TLR9 / TLR2 polymorphism stratification. No published Tα1 efficacy data by genotype. 23andMe / Promethease assessment of TLR9 / TLR2 variants is theoretically informative but not actionable.
  8. Compounding pharmacy access. Tα1 is NOT on the FDA Category 2 restricted bulks list (unlike BPC-157, TB-500). Compounding pharmacy access with physician Rx is theoretically available — would be the cleanest supply chain. Action: investigate which US peptide-aware physicians can Rx Tα1 via compounding pharmacy if the user moves to chronic prophylactic use.

References

Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials (Dinetz & Lee 2024, *Alternative Therapies in Health and Medicine*, PubMed 38308608)

pubmed.ncbi.nlm.nih.gov · 2024

meta-review across 11,000+ patients, 30+ trials, <1% serious AEs

View Study

Efficacy and Safety of Thymosin α1 for Sepsis (TESTS): Multicentre RCT Phase 3 (Zhang 2025, *BMJ*)

pubmed.ncbi.nlm.nih.gov · 2025

definitive Phase 3 negative for primary endpoint (1,106 patients)

View Study

A Pilot Trial of Thymalfasin in Hospitalized COVID-19 Patients (Shehadeh 2023, *Journal of Infectious Diseases*)

academic.oup.com · 2023

improved lymphocyte recovery, mixed clinical outcomes

View Study

Tα1 Reduces Mortality of Severe COVID-19 by Restoration of Lymphocytopenia (Liu 2020, *Clinical Infectious Diseases*)

academic.oup.com · 2020

retrospective trial, 30% → 11% mortality reduction

View Study

Tα1 Restores Immune Homeostasis in Lymphocytes During PASC (Romano 2023, *Frontiers in Immunology*)

pmc.ncbi.nlm.nih.gov · 2023

Long COVID immune restoration, 1.6 mg SC 2x/week × 12 weeks

View Study

Thymosin Alpha 1 Wikipedia

en.wikipedia.org

synthetic 28-AA peptide structure, history, Zadaxin brand, regulatory status across countries

View Source

Thymosin Alpha 1 in Severe Acute Pancreatitis Meta-Analysis (Tian 2025, *Frontiers in Immunology*)

frontiersin.org · 2025

706 patients, significant infection rate + inflammation reduction

View Source

Tα1: A Comprehensive Review of the Literature (Dominari 2020, *World Journal of Virology*)

wjgnet.com · 2020

narrative review covering mechanism + indications

View Source

TESTS Phase 3 Sepsis Trial Registration (NCT02867267)

clinicaltrials.gov

clinical trial registration for largest Tα1 RCT

View Source

Pep-pedia Thymosin Alpha 1 entry

pep-pedia.com

structured data overview, dosing protocols, indications by category

View Source
PPInteractions5 compounds▸
PeptideStatusNote
Immunosuppressive Agents
ContraindicatedAbsolute contraindication in organ transplant recipients. Fatal immune hemolytic anemia and graft rejection documented in hematopoietic stem cell transplant patients.
Corticosteroids
Monitor CombinationPharmacodynamic antagonism as Ta1 blocks steroid-induced thymocyte apoptosis, potentially reducing immunosuppressive effects.
Interferon-α
SynergisticEnhanced antiviral efficacy in hepatitis treatment with synergistic NK cell activation. Monitor for increased fever, fatigue, and neutropenia.
Vaccines
CompatibleIntended therapeutic effect enhancing vaccine immunogenicity, particularly beneficial in elderly and immunocompromised patients.
Chemotherapy Agents
CompatibleProtective effects against cytotoxic bone marrow damage while maintaining standard oncology monitoring protocols.
Source: pep-pedia.org
PP Community insights — click to load ▸
Imported from pep-pedia.org. Compounds with the PP badge use community-survey data captured from pep-pedia, who run a longer-running poll with a much larger respondent base than ours yet. Refreshed every ~6h. Our own writable poll is below for new data we collect directly.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…